develops and markets manufacturing informatics, that helps high-end regulated manufacturers
(i.e. pharmaceutical, biotechnology, medical device and food companies) to leverage
their large investment in process control data and data acquisition systems to improve
time to revenue for new products and yield quality from their existing plants.
Ganymed Pharmaceuticals AG
is developing monoclonal antibody therapeutics against solid tumors, where current
therapies are poor and where there is an overriding medical need. GANYMED's pan cancer
surface antigens are uniquely specific for cancer tissues and can be expected to
show greater therapeutic efficacy and better safety allowing significant reduction
in time to market. The Company's complementary drug development platforms are generating
a sustainable pipeline of antigen targets and monoclonal antibody leads of unique
Genomatix Software GmbH
offers software, databases and services aimed at understanding gene regulation at
the molecular level representing a central part of systems biology. Genomatix’s multilayer
integrative approach is a working implementation of systems biology principles enabling
a better understanding of biological mechanisms under different conditions and stimuli
in the biological context of your data.
Preventor µTBC GmbH
develops and commercialises innovative, compact and cost effective products in all
areas of drug safety. The main objectives are to optimize the safety profile of drugs
throughout the development pipeline, lower the attrition rates and, eventually, assist
in offering innovative drugs to patients as quickly as possible. Preventor has developed
and distributes the Drug Solubility Workstation SuperSol 1000.
develops innovative drugs and diagnostics to treat cardiovascular diseases by targeting
Vasopharm’s most advanced drug, VAS-203 for the treatment of traumatic brain injury
has entered first clinical trials.
Early Stage Fund III LP is a venture capital fund with a primary focus on high technology
companies, spinning out of the University of Wisconsin, Madison, the fourth largest
research institution of the USA. The portfolio includes three IPOs and one trade
sale to date. Two further IPOs have already been filed for 2007. The fund is performing
in the top quartile among its peers.